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INTRODUCTION
Multidrug resistance (MDR) is a major problem in
cancer chemotherapy. P-glycoprotein (P-gp), which local-
izes in the plasma membranes of MDR cells (1-3) and
transports various cytotoxic drugs to outside the cells, is
one of the key molecules in MDR (4, 5). Recently, even a
low level of P-gp expression was reported to be useful as a
marker of resistance to combination chemotherapy in
ovarian and small cell lung cancers (6). Thus, the selective
killing of tumor cells expressing P-gp seems very
important for successful cancer therapy. We reported that
MRK16 (7), a monoclonal antibody (Ab) that recognizes
the extracellular domain of human P-gp, caused rapid
regression of established s.c. MDR tumors in nude
mice (8) by Ab-dependent cellular cytotoxicity (ADCC)
mediated by macrophages (9, 10).
On the other hand, cyclosporin A (CsA) (11, 12)
reverses MDR in vitro and in vivo when combined with
antitumor agents. CsA inhibits the efflux of antitumor
agents through their binding to P-gp, resulting in
intracellular accumulation of the antitumor agents and so
overcomes drug resistance (12). The combined use of
MRK16 with CsA synergistically reversed MDR of
P-gp-positive cancer cells (13). We recently found that
CsA enhanced MRK16-dependent monocyte-mediated
cytotoxicity against MDR human cancer cells, and that
this enhancement was due to the augmentation by CsA of
the susceptibility of MDR cancer cells to monocyte-ADCC
(14). But exact mechanism is unknown.
Recently, it was found that the mouse-human chimeric
anti-GM2 Ab KM966 reacted to various human tumor cells
including lung cancer and lysed these tumor cells through
the ADCC reaction in the presence of human effector cells
(15, 16). In this study, using KM966 instead of MRK16, we
examined whether CsA enhanced the susceptibility of
multidrug-resistant cancer cells to MRK16-dependent
ADCC mediated by monocytes through its inhibitory
effect of P-gp function.
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MATERIALS AND METHODS
Cell lines
The human cell lines used in this study are listed in
Table 1. A2780 and its adriamycin-resistant variant, AD10
(also called 2780AD), were kindly supplied by Drs. R. F.
Ozols and T. C. Hamilton (National Cancer Institute) (2).
H69 cells were from the American Type Culture
Collection (Rockville, MD) and etoposide-resistant variant
of H69 cells (H69/VP) (17) were kindly provided by Dr.
N. Saijo (National Cancer Center Research Institute,
Tokyo). SBC-3 cells were from Japanese Cancer Research
Resources Bank. RERF-LC-MS and RERF-LC-AI cells (18)
were kindly provided by Dr. M. Akiyama (Radiation
Effects Research Foundation, Hiroshima). Cell cultures
were maintained in RPMI1640 supplemented with 10%
heat-inactivated fetal bovine serum and gentamicin at 37℃
in a humidified atmosphere of 5% CO2 in air. Cytotoxicity
assays were performed when the cultured target cells
were in the exponential phase of growth.
Reagents
Fetal bovine serum was purchased from M.A. Bio-
products (Walkerville, MD). CsA was provided from Sandoz
Pharmaceutical Co., Tokyo. The anti-P-gp Ab MRK16 (7)
and the mouse-human chimeric anti-GM2 Ab KM966 (16)
were purified as described previously. None of these
materials contained endotoxins, as judged by Limulus
amebocyte assay (Seikagaku Kogyo Co., Tokyo : minimum
detection level 0.1 ng/ml).
Analysis by flow microfluorometry
Tumor cells were harvested and resuspended in PBS
supplemented with 10% human pooled AB serum to
prevent nonspecific antibody binding. After incubation for
30 min at 4℃, the cells were washed once and incubated
for 30 min at 4℃ in PBS containing MRK16, KM966 (10
µg/ml) or mouse control serum (Tago, Inc., Burlingame,
CA) (10 µg/ml). The cells were then washed with PBS,
and fluorescein-conjugated goat anti-mouse IgG (H+L)
(Immunotech S.A., Marseille, France) or goat anti-human
IgG Fc (Organon Teknika, West Chester, PA) were added
as a second Ab. After 30 min-incubation at 4℃, they
were washed again and the fluorescence intensity was
measured with a FACScan (Becton Dickinson, Mountain
View, CA) (19).
Isolation and culture of human monocytes
Leukocytes from peripheral blood (200 ml) of healthy
donors were collected in an RS-6600 rotor of a Kubota
KR-400 centrifuge, and mononuclear cells (MNC) were
separated from leukocytes in lymphocyte separation
medium (Litton Bionetics). Monocytes were separated
from MNC by centrifugal elutriation in a Beckman JE-5.0
elutriation system (20). Fraction enriched in monocytes
(>95%) was obtained at 3000 rpm and flow rates of 30-36
ml/min. More than 97% of the cells were viable, as judged
by the trypan blue dye exclusion test. The monocyte
fraction was washed twice with PBS, and resuspended in
medium. These cells were plated for 1 h in 96-well
Microtest III plates (Falcon, Oxford, CA), and then
nonadherent cells were removed by washing with
medium. At this point the purity of the monocytes was
>99% as judged by their morphology and nonspecific
esterase staining.
ADCC assay
The target cells were labeled with 51Cr as described
before (14). In some experiments, 51Cr-labeled target cells
were incubated in medium for 2 h with CsA before ADCC
assay. Purified monocytes (2×105/100 µl) in 96-well
Microtest III plates were mixed with a suspension (100 µl)
of 1×104 51Cr-labeled target cells with or without various
concentrations of MRK16 or KM966 in the presence or
absence of CsA. The plates were centrifuged for 3 min at
100×g, and then incubated at 37℃ for 4 h in a humidified
5% CO2 atmosphere. After centrifugation, the radioactivity
in 100 µl of supernatant was counted in a γ-counter.
Determinations were carried out in triplicate. The
percentage of specific cytolysis was calculated from the
51Cr-releases from test samples and control samples, as
follows :
% specific lysis = (E－S) / (M－S)×100
where E is the release in the test sample (cpm in the
supernatant from target cells incubated with effector cells
and test antibody), S is the spontaneous release (cpm in
the supernatant from target cells incubated with medium
alone), and M is the maximum release (cpm released
from target cells lysed with 1 N HCl). In a preliminary
experiment there was no significant difference in the
spontaneous release between CsA-treated target cells and
untreated cells.
Statistical analysis
The statistical significance of differences between groups
was analyzed by Student's two-tailed t test. In all deter-
minations, differences were considered significant at P <
0.05.
RESULTS
Characteristics of tumor cell lines used in this study
We summarize the reactivity of various human cancer
cell lines to anti-P-gp Ab MRK16 and anti-GM2 Ab KM966
in Table 1. Staining patterns of cells with MRK16 and
KM966 are also given in Fig.1. Adriamycin-resistant
ovarian cancer cells (AD10) and etoposide-resistant lung
cancer cells (H69/VP) expressed P-gp and three of five
lung cancer cell lines expressed GM2 on their cell
surfaces. In addition, two ovarian cancer cell lines
expressed GM2 irrespective of adriamycin-resistance.
Effect of CsA on anti-GM2 Ab-dependent ADCC against
MDR ovarian cancer cells
We first examined whether the interaction of P-gp to
MRK16 Ab was necessary for augmentation by CsA of the
susceptibility of MDR cancer cells to monocyte-ADCC.
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For this, we used anti-GM2 Ab (KM966) to induce
monocyte-ADCC against AD10 cells. Monocytes were not
spontaneously cytotoxic against AD10 cells, and CsA did
not enhance this cytotoxicity in the absence of Ab. In
addition, neither control mouse IgG, control human
IgG, nor MRK16 F(ab')2 enhanced monocyte-mediated
cytotoxicity irrespective of the presence of CsA (data not
shown). Both MRK16 and KM966 caused significant
increase in the monocyte-mediated cytotoxicity against
AD10 cells (Fig 2 A, B), which was significantly enhanced
by addition of CsA.
Effect of CsA on monocyte-ADCC against P-gp-negative
ovarian cancer cells
We next examined whether the inhibition of P-gp
function by CsA is correlated to the enhancement by CsA
of monocyte-ADCC against MDR cells. For this, we used
A2780 cells, which were P-gp-negative parent cell line
of AD10 cells, as target cells. Monocytes were not
spontaneously cytotoxic to A2780 cells. The cytotoxicity
was not augmented by addition of MRK16 nor CsA (data
not shown). KM966 induced monocyte-ADCC against
A2780 cells and CsA significantly augmented this ADCC
(Fig.3).
Effect of pretreatment of target cells with CsA on ADCC
We previously reported (14) that CsA modified MDR
cancer cells to become susceptible to MRK16-dependent
monocyte-ADCC. To determine whether CsA could affect
the susceptibility of target cells to KM966-dependent
ADCC, we pretreated target cells with CsA for 2 h. More
than 99% of target cells treated with CsA (30 mg/ml) were
viable by the trypan blue dye exclusion test, and there
was no significant difference in proliferation between
CsA-treated and untreated cells (data not shown).
Pretreatment of the target cells with CsA did not
affect spontaneous monocyte-mediated cytotoxicity against
AD10 and A2780 cells in the absence of Ab. In the same
Table 1. Characteristics of human cancer cell lines used in this study
Cell line Origin
Surface antigen Enhancement of ADCC by CsA
P-gp GM2 MRK16 KM966
AD10 (A2780AD)
A2780
H69
H69/VP
SBC-3
RERF-LC-MS
RERF-LC-AI
Ovarian cancer
Ovarian cancer
Lung cancer (Small cell)
Lung cancer (Small cell)
Lung cancer (Small cell)
Lung cancer (Adeno)
Lung cancer (Squamous cell)
＋
－
－
＋
－
－
－
＋
＋
＋
－
＋
＋
－
＋
－
－
－
－
－
－
＋
＋
－
－
－
－
－
Fig.1. P-gp and GM2 expression on various human cancer cell lines used in this study. Tumor cells were stained with MRK16 (dotted line),
KM966 (solid line), or control Ab (dashed line). P-gp and GM2 expression was examined as described in "Materials and Methods."
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experimental conditions, CsA significantly increased the
sensitivity of both AD10 and A2780 cells to ADCC by
monocytes in the presence of KM966 (Fig.4 A, B).
Effect of CsA on monocyte-ADCC against various lung
cancer cells
In the previous study (14), we found that CsA augmented
the sensitivity to monocyte-ADCC of various tumor cell lines
such as K 562/ADM (adriamycin-resistant erythroleukemia)
and KB-C4 (colchicine-resistant epidermoid carcinoma)
cells as well as AD10 cells. Etoposide-resistant small
cell lung carcinoma cells H69/VP expressed P-gp as
shown in Fig.1. We next examined effect of CsA on
MRK 16-dependent monocyte-mediated cytotoxicity against
H69/VP cells. Interestingly, while optimal dose of MRK16
(1 µg/ml) significantly induced ADCC activity against
P-gp positive H69/VP cells, this ADCC activity was not
augmented by addition of CsA (up to 30 µg/ml) (Fig.5 A).
Fig.2. Effect of CsA on anti-GM2 Ab-dependent ADCC against MDR
ovarian cancer cells. 51Cr-labeled AD10 cells were incubated with
monocytes with MRK16 or KM966 in the presence or absence of
CsA. E/T ratio was 20. Percent cytotoxicity was determined as
described in "Materials and Methods." Bars show SDs of means
for triplicate cultures. Data are representative of three separate
experiments.
Fig.3. Effect of CsA on monocyte-ADCC against P-gp-negative
ovarian cancer cells. 51Cr-labeled A2780 cells were incubated with
monocytes with MRK16 or KM966 in the presence or absence of
CsA. E/T ratio was 20. Percent cytotoxicity was determined as
described in "Materials and Methods." Bars show SDs of means for
triplicate cultures. Data are representative of three separate
experiments.
Fig.4. Effect of pretreatment of target cells with CsA on ADCC.
51Cr-labeled target cells were incubated in medium with or without
CsA (30 µg/ml) for 2 h at 37℃, then washed. The resultant cells
were incubated with monocytes in the presence or absence of
MRK16 (1 µg/ml) or KM966 (1 µg/ml). E/T ratio was 20. Percent
cytotoxicity was determined as described in "Materials and
Methods." Bars show SDs of means for triplacate cultures. Data are
representative of two separate experiments.
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We also examined the effect of CsA in the presence of
suboptimal dose of MRK16 (0.1 µg/ml), but CsA did not
enhance ADCC against H69/VP cells (Fig.5B). Moreover,
KM966 did not induce monocyte-ADCC against H 69/VP
cells, irrespective of the presence of CsA (data not shown).
We next examined the effect of CsA on monocyte-
ADCC against various human lung cancer cells in the
presence of anti-GM2 Ab, KM966. For this, in addition to
A2780 and AD10 cells as a control, we used four human
lung cancer cell lines with different levels of GM2
expression on cell surface. Fig.6 shows that KM966
induced ADCC against A2780 and AD10 cells, which was
significantly augmented by CsA. In contrast, KM966
induced no significant ADCC against RERF-LC-AI cells
which had no GM2, and CsA did not affect the
cytotoxicity. KM966 induced monocyte-ADCC against
GM2-positive lung cancer cells (H69, SBC-3, and
RERF-LC-MS), These ADCC were not enhanced by
addition of CsA. Moreover, MRK16 did not induce
monocyte-ADCC against these lung cancer cell lines,
irrespective of the presence of CsA (data not shown).
DISCUSSION
We previously reported (14) that CsA enhanced the
susceptibility of P-gp-positive MDR cancer cells to MRK16-
dependent ADCC by monocytes. This study was conducted
to clarify whether CsA enhanced the susceptibility of
MDR cancer cells through its inhibitory effect on P-gp
function.
Here, we found that CsA augmented the susceptibility
to monocyte-ADCC of ovarian cancer cells irrespective of
the expression of P-gp, indicating that suppressive effect
on P-gp function by CsA was not essential to enhance
ADCC of MDR cancer cells. One possible mechanism
presented in a previous report (14) to explain the
enhanced ADCC by CsA was that CsA might enhance the
susceptibility of MDR cancer cells through the increased
intracellular accumulation of cytotoxic products, resulting
in secondary membrane damage and cell death. Because
P-gp might mediate efflux of not only antitumor agents
but also waste and cytotoxic products (5, 21). But this
possibility was ruled out by the findings in the present
study.
Monocytes are known to produce complement when
they are activated with stimuli (22). CsA also enhanced
complement-mediated cytolysis against MDR ovarian
cancer cells in the presence of MRK16 as described
previously (14), indicating that CsA enhanced membrane
damage. Moreover, because augmented ADCC by CsA of
MDR cancer cells was partially inhibited by catalase
(inhibitor of hydrogen peroxide), we presume that
complement and hydrogen peroxide might be effector
molecules from monocytes in ADCC reaction and that
CsA might enhance the susceptibility of MDR cancer cells
to such molecules. On the other hand, CsA is known to
bind to phospholipid vesicles (23), interferes with the
incorporation of fatty acids into membrane phospholipids
(24) and depolarizes the cytoplasmic membrane (25).
Therefore, CsA may modify plasma membrane of cancer
cells coated with Ab to become susceptible to complement
and hydrogen peroxide from monocytes.
We reported (14) that CsA augmented the susceptibility
of various human MDR cancer cell lines such as AD10,
K562/ADM, and KB-C4 cells to monocyte-ADCC. But it
was not the same in the case of human lung cancer cell
lines irrespective of the expression of P-gp. CsA, however,
efficiently reversed vincristine-resistance of P-gp-positive
lung cancer cells (H69/VP) (data not shown). Moreover,
Glissont, et al . also reported (26) that CsA enhanced
accumulation of etoposide in MDR H69 cells (VPR-2) to
overcome their etoposide resistance, indicating that CsA
could inhibit drug transport by P-gp expressed on human
lung cancer cells. Because complement-mediated cytolysis
against H69/VP cells in the presence of MRK16 was not
augmented by addition of CsA (data not shown), plasma
Fig.5. Effect of CsA on monocyte-ADCC against MDR lung cancer
cells. 51Cr-labeled H69/VP cells were incubated with monocytes with
MRK16 in the presence or absence of CsA. E/T ratio was 20.
Percent cytotoxicity was determined as described in "Materials and
Methods." Bars show SDs of means for triplicate cultures. Data are
representative of three separate experiments.
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membrane of lung cancer cells may not be the same as
that of others (e.g., ovarian cancer cells) on sensitivity to
CsA. However, the reason why CsA did not affect the
susceptibility of lung cancer cells to monocyte-ADCC is
still unknown. Further examinations to clarify the
mechanism of insufficient effect of CsA on ADCC against
lung cancer may be useful for developing novel
therapeutic strategy to lung cancer.
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